ERBB2 and breast carcinoma: In particular, vaccines targeting HER-2 have been developed in preclinical and clinical studies, and may be promising for the enhancement of the antitumor immune response through the provision of CTLs and memory CTLs in combination with HER-2-targeting agents for different HER-2 expression levels in patients with breast cancer [133].